查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1809756

全球抗生素抗藥性市場（按服務、病原體類型、感染類型和最終用途）預測（2025-2030 年）

Antibiotic Resistance Market by Offering, Pathogen Type, Infection Type, End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球抗生素抗藥性市場規模為 75.1 億美元，預計 2025 年將達到 79.6 億美元，複合年成長率為 6.12%，到 2030 年將達到 107.3 億美元。

主要市場統計數據
基準年：2024年 75.1億美元
預計年份：2025年 79.6億美元
預測年份：2030年 107.3億美元
複合年成長率（%） 6.12%

了解醫療保健系統中日益嚴峻的抗生素抗藥性挑戰以及全球相關人員面臨的關鍵問題

隨著抗生素抗藥性以前所未有的速度加劇，全球醫療體係正面臨嚴峻危機。曾經易受標準療法影響的病原體正在進化機制，以逃避我們曾經可靠的藥物庫。結果，社區面臨更長的住院時間、更高的醫療成本和更高的死亡率。在這種情況下，理解科學創新、政策改革和臨床實踐之間的相互作用至關重要。

繪製抗生素開發平臺、法規結構和全球衛生政策的變革性變化，重塑治療策略和市場現實

一系列科學突破、監管格局的調整以及資金籌措機制的演變，正在重塑抗生素格局。近年來，自適應試驗設計加速了候選藥物的篩檢，而人工智慧和機器學習平台簡化了標靶識別和先導化合物的最佳化。同時，監管機構正在推出獎勵，以促進新藥開發，強調向基於價值的核准路徑和快速審查的模式轉移。

評估2025年美國關稅政策對抗生素供應鏈研發投入和市場進入的深遠影響

美國於2025年實施的關稅措施，為抗生素供應鏈的平衡引入了一個新變數。透過提高關鍵中間體、成品製劑和關鍵原料的關稅，這些政策已波及整個生產流程，導致單位成本上升，利潤率受到擠壓。成本基數的增加促使採購團隊重新協商供應商契約，並探索其他採購方案，從而改變了根深蒂固的供應鏈關係。

按產品、病原體類型、感染類型和最終用途類別進行市場細分，以確定目標商業機會和策略挑戰

穩健的細分框架揭示了不同的策略潛力和抗藥性挑戰。依應用類型分類，Aminoglycosides對革蘭氏陰性菌表現出強效殺菌活性，但由於其治療指數較窄，需要密切監測。頭孢菌素類藥物具有廣譜抗菌譜，但在院內感染中抗藥性較高。同時，儘管有腎毒性的擔憂，醣肽仍然是治療嚴重革蘭氏陽性感染疾病的主要藥物。Oxazolidinone、磺胺類藥物和四環黴素在作用機轉和安全性方面各有特色，需要採取量身訂做的管理方法。

確定美洲、歐洲、中東和非洲地區以及亞太地區的市場動態，突顯市場促進因素和挑戰

抗生素抗藥性的動態和戰略重點因地區而異。在美洲，成熟的監管途徑和報銷框架支持採用先進的治療創新。然而，頻譜藥物在門診病人的廣泛使用加速了抗藥性表現型的出現，導致更嚴格的管理指南和處方限制。同時，拉丁美洲市場受到供應鏈不一致和監管實施差異的困擾，導致高風險病原體在區域性疫情爆發。

分析抗生素研發和商業化的大型製藥企業和新興創新者，揭示他們的競爭策略、產品系列和合作網路

一群老牌製藥公司憑藉其多元化的產品系列和廣泛的全球影響力，持續支撐著抗生素市場。這些行業領導者優先採取平衡的策略，逐步改進現有抗生素類別，並投資於噬菌體療法和抗菌肽等突破性治療方法。同時，新興生技公司則專注於精準標靶機制，利用先進的篩檢平台發現不易產生抗藥性的新型支架，從而開拓利基市場。

為產業領導者制定可行的策略建議，以加強抗生素管理、推動創新、加強合作並降低抗藥性風險

產業領導者必須採取多管齊下的策略策略，有效應對抗生素抗藥性情勢。首先，加強抗生素管理計畫至關重要。這包括將決策支援工具納入電子健康記錄，以指導處方醫師選擇最佳給藥方案和窄頻譜藥物。其次，企業應加快早期發現平台的投資，優先考慮能夠規避現有抗藥性機制的新標靶和創新治療方法。

嚴謹的調查方法的細節，結合定性專家諮詢、定量數據分析和全面的二次研究，以確保分析的穩健性

本報告採用嚴謹、多層次的調查方法，以確保分析的穩健性和事實的準確性。主要研究包括對30多位製藥公司高階主管、臨床微生物學家、政策顧問以及感染疾病控制領域的關鍵意見領袖的深入訪談。這些訪談揭示了關於策略重點、營運挑戰和市場預期的定性背景。

整合對日益成長的市場轉型和抗生素抗藥性策略路徑的關鍵洞察，為決策者提供清晰的洞察力，以便進行主動規劃

抗生素抗藥性已超越單純的臨床問題，成為一項決定性的政策、經濟和公共衛生挑戰。不斷變化的情況要求相關人員採取整合策略，將創新研究、靈活的監管參與和強力的管理結合起來，以保障現有治療方法的有效性，同時加速新治療方法的研發。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 針對多重抗藥性革蘭氏陰性病菌感染的新型BETA-內醯胺酶抑制劑的出現
  • 將快速分子診斷融入醫院環境以最佳化抗生素管理
  • 噬菌體療法在應對抗生素抗藥性病原體方面取得進展
  • 人工智慧驅動的抗生素發現平台的成長將加速先導藥物最適化
  • 在中低收入國家擴大全球抗生素管理項目
  • 監管獎勵和推拉式資金籌措模式推動抗生素研發創新
  • 開發基於 CRISPR 的抗菌劑，精確靶向病原體
  • 引入微生物調節療法來預防感染並減少抗生素依賴
  • 生技公司與大型製藥公司合作開發新型抗生素，以填補研發管線空白

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章抗生素抗藥性市場：透過提供

  • 聯合治療
  • 藥物
    • Aminoglycosides
    • BETA-內醯胺類
    • Fluoroquinolones
    • 糖肽
    • 大環內酯類
    • Oxazolidinone
    • 多粘菌素
    • 磺胺類藥物
    • 四環黴素
  • 免疫調節藥物
  • 單株抗體
  • 噬菌體療法

9. 抗生素抗藥性市場（依病原體類型）

  • 鮑曼不動鮑氏不動桿菌（A. baumannii）
  • 大腸桿菌
  • 肺炎克雷伯菌（K. pneumoniae）
  • 銅綠假單胞菌
  • 金黃色葡萄球菌（S. aureus）
  • 肺炎鏈球菌

第 10 章抗生素抗藥性市場（依感染類型）

  • 急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）
  • 血流感染疾病（BSI）
  • 困難梭狀桿菌感染疾病（CDI）
  • 社區型細菌性肺炎（CABP）
  • 複雜性尿道感染（cUTI）

第 11 章抗生素抗藥性市場：依最終用途

  • 門診治療中心
  • 診斷實驗室
  • 醫院和診所
  • 研究所

12. 美洲抗生素抗藥性市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲的抗生素抗藥性市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14. 亞太地區抗生素抗藥性市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Basilea Pharmaceutica Ltd
    • bioMerieux SA
    • Cipla Limited
    • Cumberland Pharmaceuticals
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Innoviva, Inc.
    • Johnson & Johnson Services, Inc.
    • Novo Holdings A/S
    • Pfizer Inc.
    • Sandoz AG
    • Shionogi & Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-535C629188E6

The Antibiotic Resistance Market was valued at USD 7.51 billion in 2024 and is projected to grow to USD 7.96 billion in 2025, with a CAGR of 6.12%, reaching USD 10.73 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 7.51 billion
Estimated Year [2025] USD 7.96 billion
Forecast Year [2030] USD 10.73 billion
CAGR (%) 6.12%

Unveiling the Escalating Challenge of Antibiotic Resistance Across Healthcare Systems and the Critical Imperatives for Stakeholders Worldwide

Healthcare systems around the globe are confronting a mounting crisis as antibiotic resistance accelerates at an unprecedented pace. Pathogens that were once susceptible to standard treatments are evolving mechanisms to evade the once-reliable weapons in our pharmaceutical arsenal. As a result, communities face longer hospital stays, higher medical costs, and a growing mortality burden. In this context, understanding the interplay of scientific innovation, policy reform, and clinical practice has become critical.

Stakeholders across the continuum-from policy-makers to hospital administrators, from research institutions to pharmaceutical executives-must navigate this volatile environment. They require not only real-time visibility into emerging resistance patterns but also a holistic strategy that aligns discovery pipelines with stewardship initiatives. This introductory section lays the groundwork by framing antibiotic resistance as both a public health emergency and a catalyst for transformative industry responses.

Mapping the Transformative Shifts in Antibiotic Development Pipelines Regulatory Frameworks and Global Health Policies Reshaping Therapeutic Strategies and Market Realities

The antibiotic landscape is being reshaped by a confluence of scientific breakthroughs, regulatory recalibrations, and evolving funding mechanisms. In recent years, adaptive trial designs have accelerated candidate screening, while artificial intelligence and machine learning platforms have streamlined target identification and lead optimization. Simultaneously, regulatory bodies have introduced incentives to stimulate development of novel agents, underscoring a paradigm shift toward value-based approval pathways and expedited reviews.

Moreover, collaborations between public institutions, non-profit consortia, and private enterprises are forging new models for risk sharing and resource pooling. These partnerships are fundamental to overcoming the traditional barriers of cost and complexity, especially in late-stage clinical trials where financial exposure can be prohibitive. Accordingly, we are witnessing a strategic realignment in which stakeholder networks are moving beyond transactional alliances to enduring consortiums, thereby distributing both risk and reward more equitably across the antibiotic innovation ecosystem.

At the same time, global health policies are adjusting to the reality that stewardship and access must be balanced. Initiatives aimed at curbing overuse are now being integrated with mechanisms to ensure equitable distribution, particularly in low- and middle-income nations. The result is a more nuanced regulatory environment that demands adaptive commercial strategies and informed advocacy efforts to synchronize market entry with public health objectives.

Assessing the Far-Reaching Consequences of United States Tariff Policies on Antibiotic Supply Chains R&D Investments and Market Accessibility in 2025

United States tariff measures introduced in 2025 have introduced a new variable into the antibiotic supply chain equation. By raising duties on critical intermediates, finished dosage forms, and key raw materials, these policies have cascaded through manufacturing workflows, elevating unit costs and exerting pressure on profit margins. The increased cost base has spurred procurement teams to renegotiate supplier contracts and explore alternative sourcing arrangements, thereby altering entrenched supply-chain relationships.

In parallel, the tariff landscape has prompted multinational companies to reassess their production footprints. Some organizations have initiated feasibility studies to relocate manufacturing closer to end markets or to establish dual-sourcing agreements to mitigate exposure. Consequently, lead times have lengthened for certain molecule classes, introducing variability in inventory cycles and compelling downstream stakeholders to build additional stock buffers to safeguard against potential disruptions.

Perhaps most impactful is the ripple effect on research and development budgets. As companies absorb tariff-related cost increases, discretionary funding for early-stage research faces tighter scrutiny. Projects targeting high-risk pathogen classes may experience reprioritization, while investment committees demand clearer return-on-investment thresholds. This environment compels a recalibration of portfolio strategies, emphasizing asset triage and the pursuit of collaborative funding mechanisms to share developmental costs and expedite time-to-proof of concept.

Deconstructing Market Segmentation Across Drug Classes Pathogen Types Infection Variants and End Use Categories to Illuminate Targeted Opportunities and Strategic Imperatives

A robust segmentation framework illuminates distinct pockets of strategic potential and resistance challenges. Across drug classes, Aminoglycosides exhibit potent bactericidal action against Gram-negative organisms but carry a narrow therapeutic index that necessitates vigilant monitoring. Cephalosporins offer broad-spectrum coverage yet have encountered elevated resistance rates in hospital-acquired infections. Combination Therapies are increasingly favored for their synergistic efficacy against multidrug-resistant strains, while Glycopeptides remain a mainstay for severe Gram-positive infections despite concerns of nephrotoxicity. Oxazolidinones, Sulfonamides, and Tetracyclines each present unique profiles in terms of mechanism of action and safety considerations, prompting tailored stewardship approaches.

On the pathogen front, Acinetobacter baumannii has emerged as a formidable adversary in critical care settings, leveraging adaptive efflux pumps and biofilm formation to thwart intervention. Escherichia coli continues to drive community and hospital onset urinary tract infections, with plasmid-mediated resistance genes proliferating across geographic regions. Klebsiella pneumoniae maintains a high prevalence in ventilator-associated pneumonia, often harboring carbapenemase enzymes that render last-resort treatments ineffective. Pseudomonas aeruginosa's intrinsic resistance coupled with its ability to acquire novel determinants has cemented its status as a priority pathogen. Meanwhile, Staphylococcus aureus and Streptococcus pneumoniae persist as leading causes of both invasive and non-invasive infections, despite decades of targeted vaccine and antibiotic development.

Infection type segmentation reveals that Acute Bacterial Skin & Skin Structure Infections pose a persistent challenge in outpatient and surgical wound contexts, while Bloodstream Infections demand urgent, broad-spectrum coverage to prevent systemic spread. Clostridioides difficile Infection has surged in frequency and severity, prompting focus on narrow-spectrum therapies and microbiome-based interventions. Community-Acquired Bacterial Pneumonia remains a critical driver of hospital admissions, particularly among vulnerable elderly populations, and Complicated Urinary Tract Infections underscore the need for agents with both potent activity and favorable safety profiles.

End-use categories further refine strategic focus. Ambulatory Care Centers are driving demand for oral formulations and outpatient infusion services. Diagnostic Laboratories play an increasingly central role in rapid pathogen identification and susceptibility profiling, accelerating the shift from empirical to precision prescribing. Hospitals & Clinics continue to dominate acute-care utilization, necessitating robust formulary strategies and integrated stewardship protocols. Research Institutes serve as incubators for next-generation modalities, advancing preclinical platforms that may redefine the future of antibiotic discovery.

Delineating Regional Market Dynamics Across the Americas Europe Middle East Africa and Asia Pacific to Highlight Growth Drivers and Emerging Challenges

Regional heterogeneity continues to shape antibiotic resistance dynamics and strategic priorities. In the Americas, well-established regulatory pathways and reimbursement frameworks support the adoption of advanced therapeutic innovations. However, the pervasive use of broad-spectrum agents in outpatient settings has accelerated the emergence of resistant phenotypes, leading to more stringent stewardship guidelines and formulary restrictions. Meanwhile, Latin American markets are grappling with inconsistent supply chains and variable regulatory enforcement, contributing to localized outbreaks of high-risk pathogens.

Across Europe, Middle East & Africa, fragmented healthcare infrastructures and varying levels of access to diagnostic technology complicate coordinated stewardship efforts. In Western Europe, centralized procurement and pan-regional surveillance networks have enabled more cohesive responses to resistance trends. By contrast, emerging markets in the Middle East and Africa face challenges in laboratory capacity, cold-chain logistics, and regulatory alignment, driving reliance on off-patent generics and impeding uptake of novel agents.

Asia-Pacific presents a dual narrative of rapid innovation and persistent public health hurdles. Markets such as Japan, Australia, and South Korea boast sophisticated R&D ecosystems and proactive policy frameworks. At the same time, densely populated regions in Southeast Asia and South Asia experience high rates of antibiotic consumption, often driven by over-the-counter availability and under-resourced stewardship programs. This juxtaposition underscores both the promise of regional leadership in next-generation therapies and the imperative for coordinated cross-border initiatives to curb resistance transmission.

Analyzing Leading Pharmaceutical Players and Emerging Innovators Across Antibiotic R&D and Commercialization to Uncover Competitive Strategies Product Portfolios and Collaborative Networks

A cadre of established pharmaceutical companies continues to anchor the antibiotic market through diversified product portfolios and expansive global reach. These industry leaders prioritize a balanced approach between incremental improvements to existing classes and investments in breakthrough modalities, such as bacteriophage therapies and antimicrobial peptides. Meanwhile, emerging biotechs are carving out niche positions by focusing on precision-targeted mechanisms, leveraging advanced screening platforms to unearth novel scaffolds with reduced propensity for resistance development.

Strategic alliances have become a hallmark of the competitive landscape. Cross-sector partnerships between pharma giants and biotech innovators facilitate agile progression of assets through preclinical validation into early clinical trials. At the same time, consortium models-often supported by government grants and non-profit funding-are aggregating pooled resources to de-risk the development of ultra-narrow-spectrum candidates against priority pathogens.

In the commercialization phase, companies are adopting dynamic pricing and value-based contracting arrangements, linking reimbursement to real-world outcomes data. Such initiatives reflect a growing emphasis on aligning stakeholder incentives to reward both clinical efficacy and responsible utilization. As a result, entities that can demonstrate robust pharmacovigilance mechanisms and post-market surveillance capabilities are gaining a competitive edge, reinforcing the notion that superior product performance extends beyond the laboratory bench.

Formulating Actionable Strategic Recommendations for Industry Leaders to Enhance Antibiotic Stewardship Drive Innovation Strengthen Collaborations and Mitigate Resistance Risks

Industry leaders must adopt a multifaceted strategic playbook to navigate the antibiotic resistance landscape effectively. First, strengthening antimicrobial stewardship programs is paramount; this includes embedding decision-support tools within electronic health records to guide prescribers toward optimal dosing regimens and narrow-spectrum selections. Second, firms should accelerate investment in early-stage discovery platforms, prioritizing novel targets and innovative modalities that circumvent existing resistance mechanisms.

Simultaneously, fostering cross-sector collaboration will amplify impact. Pharmaceutical companies, academic institutions, and non-profit foundations should co-create funding consortia aimed at de-risking high-value projects. By sharing precompetitive data and co-developing clinical trial networks, these alliances can streamline development timelines and distribute financial exposure.

Engagement with regulatory bodies is equally critical. Companies must proactively shape policy dialogues on breakthrough therapy designations, adaptive licensing frameworks, and reimbursement models tied to long-term efficacy data. Clear, evidence-driven advocacy can help align public health objectives with commercial incentives, ensuring that novel agents reach patients without undue delay.

Finally, leveraging real-world evidence and digital health solutions will differentiate market leaders. Telemedicine platforms, rapid diagnostic integration, and post-market surveillance apps can provide granular usage and outcome data. By harnessing these insights, organizations can refine clinical guidelines, demonstrate value to payers, and reinforce responsible prescribing practices across care settings.

Detailing the Rigorous Research Methodology Combining Qualitative Expert Consultations Quantitative Data Analysis and Comprehensive Secondary Research to Ensure Analytical Robustness

This report is underpinned by a rigorous, multi-layered research methodology designed to ensure analytical robustness and factual precision. Primary research comprised in-depth interviews with over 30 senior executives across pharmaceutical companies, clinical microbiologists, policy advisors, and key opinion leaders in infectious disease management. These conversations provided qualitative context around strategic priorities, operational challenges, and market expectations.

Quantitative data collection drew on a wide array of reputable sources, including peer-reviewed journals, regulatory agency publications, hospital procurement records, and patient outcome registries. Data points were meticulously validated through cross-referencing and triangulation to safeguard against bias or inconsistency. In addition, supply chain analytics were integrated to model cost impacts, inventory flows, and lead-time variability under different tariff scenarios.

Secondary research efforts encompassed a comprehensive review of treatment guidelines, policy whitepapers, and global surveillance reports. Special attention was given to emerging regulatory directives and stewardship frameworks, enabling a nuanced understanding of how shifting policies influence both clinical practice and commercial strategy.

Finally, all insights underwent rigorous peer review by an internal panel of domain experts to confirm accuracy, relevance, and forward-looking applicability. This layered approach ensures that conclusions and recommendations are grounded in both empirical evidence and strategic foresight.

Synthesizing Critical Findings on Antibiotic Resistance Escalation Market Transformations and Strategic Pathways to Equip Decision Makers with Clear Insight for Proactive Planning

Antibiotic resistance has transcended a purely clinical concern to become a defining challenge that intersects policy, economics, and public health. The evolving landscape demands that stakeholders adopt integrated strategies, combining innovative research, agile regulatory engagement, and robust stewardship to safeguard the efficacy of existing therapies while accelerating the advent of new ones.

Strategic segmentation by drug class, pathogen type, infection variant, and end use has revealed differentiated areas of focus, guiding targeted investment and commercialization plans. Meanwhile, regional dynamics underscore the need for tailored approaches that reflect local infrastructure, regulatory environments, and cultural prescribing habits. In this complex ecosystem, leading companies are leveraging partnerships, adaptive trial designs, and digital tools to maintain competitive momentum. Looking ahead, the most successful entities will be those that align stakeholder incentives, embrace data-driven decision making, and foster collaborative networks across the public and private sectors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Emergence of novel beta-lactamase inhibitors targeting multidrug-resistant gram-negative infections
  • 5.2. Integration of rapid molecular diagnostics in hospital settings to optimize antibiotic stewardship
  • 5.3. Advancements in bacteriophage therapy pipelines addressing antibiotic recalcitrant pathogens
  • 5.4. Growth of AI-driven antibiotic discovery platforms for accelerated lead optimization
  • 5.5. Expansion of global antimicrobial stewardship programs in low and middle income countries
  • 5.6. Regulatory incentives and push-pull funding models driving innovation across antibiotic R&D
  • 5.7. Development of CRISPR-based antimicrobial agents for precise pathogen targeting
  • 5.8. Adoption of microbiome modulation therapies to prevent infection and reduce antibiotic reliance
  • 5.9. Biotech and big pharma collaborations focusing on novel antibiotic classes to fill pipeline gaps

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Antibiotic Resistance Market, by Offering

  • 8.1. Introduction
  • 8.2. Combination Therapies
  • 8.3. Drugs
    • 8.3.1. Aminoglycosides
    • 8.3.2. Beta-Lactams
    • 8.3.3. Fluoroquinolones
    • 8.3.4. Glycopeptides
    • 8.3.5. Macrolides
    • 8.3.6. Oxazolidinones
    • 8.3.7. Polymyxins
    • 8.3.8. Sulfonamides
    • 8.3.9. Tetracyclines
  • 8.4. Immunomodulators
  • 8.5. Monoclonal Antibodies
  • 8.6. Phage Therapy

9. Antibiotic Resistance Market, by Pathogen Type

  • 9.1. Introduction
  • 9.2. Acinetobacter Paumannii (A. baumannii)
  • 9.3. Escherichia Coli (E. coli)
  • 9.4. Klebsiella Pneumoniae (K. pneumoniae)
  • 9.5. Pseudomonas Aeruginosa (P. aeruginosa)
  • 9.6. Staphylococcus Aureus (S. aureus)
  • 9.7. Streptococcus Pneumonia (S. pneumoniae)

10. Antibiotic Resistance Market, by Infection Type

  • 10.1. Introduction
  • 10.2. Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
  • 10.3. Bloodstream Infections (BSI)
  • 10.4. Clostridioides difficile Infection (CDI)
  • 10.5. Community-Acquired Bacterial Pneumonia (CABP)
  • 10.6. Complicated Urinary Tract Infections (cUTI)

11. Antibiotic Resistance Market, by End Use

  • 11.1. Introduction
  • 11.2. Ambulatory Care Centers
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics
  • 11.5. Research Institutes

12. Americas Antibiotic Resistance Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Antibiotic Resistance Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Antibiotic Resistance Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Basilea Pharmaceutica Ltd
    • 15.3.4. bioMerieux S.A.
    • 15.3.5. Cipla Limited
    • 15.3.6. Cumberland Pharmaceuticals
    • 15.3.7. F. Hoffmann-La Roche Ltd
    • 15.3.8. GlaxoSmithKline plc
    • 15.3.9. Innoviva, Inc.
    • 15.3.10. Johnson & Johnson Services, Inc.
    • 15.3.11. Novo Holdings A/S
    • 15.3.12. Pfizer Inc.
    • 15.3.13. Sandoz AG
    • 15.3.14. Shionogi & Co., Ltd.
    • 15.3.15. Teva Pharmaceutical Industries Ltd.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. ANTIBIOTIC RESISTANCE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. ANTIBIOTIC RESISTANCE MARKET: RESEARCHAI
  • FIGURE 24. ANTIBIOTIC RESISTANCE MARKET: RESEARCHSTATISTICS
  • FIGURE 25. ANTIBIOTIC RESISTANCE MARKET: RESEARCHCONTACTS
  • FIGURE 26. ANTIBIOTIC RESISTANCE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ANTIBIOTIC RESISTANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 123. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 124. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 131. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 132. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 133. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 134. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 135. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 140. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 163. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 164. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 165. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 166. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 167. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 172. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 174. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 176. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 182. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 183. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 184. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 185. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 186. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 187. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 192. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 194. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 196. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 202. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 203. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 204. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 205. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 206. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 212. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 223. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 224. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 225. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 226. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 227. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 233. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 234. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 243. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 244. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 245. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 246. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 247. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 252. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 253. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 254. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 255. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 256. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 262. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 263. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 264. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 265. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 266. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 267. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 271. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 272. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 273. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 274. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 275. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 276. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 277. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 282. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 283. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 284. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 285. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 286. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 287. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 292. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 293. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 294. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 295. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 296. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 297. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 302. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 303. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 304. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 305. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 306. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 307. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 312. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 313. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 314. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 315. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 316. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 317. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 321. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 322. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 323. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 324. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 325. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 326. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 327. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 329. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2025-2030 (USD MILLION)
  • TABLE 331. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 332. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 333. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 334. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2025-2030 (USD MILLION)
  • TABLE 335. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 336. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
  • TABLE 337. N